Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing – Retrospective Review Of The SWOG Experience

Min Fang, MD, PhD, Shannon McDonough, Megan Othus, PhD, Lily T Zhuo, Diane Roulston, Ph.D., Harry Paul Erba, MD, PhD, Frederick R. Appelbaum, MD

Blood (2013) 122 (21): 1383.

https://doi.org/10.1182/blood.V122.21.1383.1383

Published: 2013

Journal Articles

Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Blood (2013) 122 (21): 3903.

https://doi.org/10.1182/blood.V122.21.3903.3903

Published: 2013

Journal Articles

Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study

Thomas Prebet, MD, PhD, Zhuoxin Sun, PhD, Rhett Ketterling, MD, Peter L. Greenberg, MD, Amer M. Zeidan, MD, Mark R. Litzow, MD, Janice L. Gabrilove, MD, Harry Paul Erba, MD, PhD, Elisabeth Paietta, PhD, Magdalena Czader, MD, PhD, Steven D Gore, Martin S Tallman, MD

Blood (2013) 122 (21): 2777.

https://doi.org/10.1182/blood.V122.21.2777.2777

Published: 2013

Journal Articles

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

Megan Othus, PhD, Hagop M. Kantarjian, MD, Stephen Petersdorf, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Sherry A. Pierce, RN, BS, Harry Paul Erba, MD, PhD, Stefan Faderl, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 129.

https://doi.org/10.1182/blood.V120.21.129.129

Published: 2012

Journal Articles

A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients

Sucha Nand, MD, Megan Othus, PhD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Thomas Norwood, Harry Paul Erba, MD, PhD, Dianna Howard, MD, Steven E. Coutre, MD, Frederick R. Appelbaum, MD

Blood (2012) 120 (21): 3584.

https://doi.org/10.1182/blood.V120.21.3584.3584

Published: 2012

Journal Articles

Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I Study

Geoffrey L. Uy, MD, David Avigan, MD, Jorge E. Cortes, Pamela S. Becker, MD, PhD, Robert W. Chen, MD, Jane L. Liesveld, MD, Becker Hewes, MD, Don Johns, Harry Paul Erba, MD, PhD

Blood (2011) 118 (21): 82.

https://doi.org/10.1182/blood.V118.21.82.82

Published: 2011

Journal Articles

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, PhD, Stephen Petersdorf, MD, Harry Paul Erba, MD, PhD, Richard M. Stone, MD, Soheil Meshinchi, MD, PhD, Thomas J. Nevill, MD, FRCPC, Jerald P. Radich, MD, Leif Stenke, MD, PhD, Marilyn L Slovak, PhD, Robert K Stuart, MD, Martin S. Tallman, MD, Cheryl L Willman, MD, Rebecca M. Mortensen, Breanna L. Wentz, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2011) 118 (21): 2520.

https://doi.org/10.1182/blood.V118.21.2520.2520

Published: 2011

Journal Articles

Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia.

Sami Malek, MD, Peter Ouillette, Yin Wang, Yan Liu, Whitney Wright, Diane Roulston, Amanda L Dressel, RN, BSN, Judith Karp, Paula Bockenstedt, MD, Ammar Al-Zoubi, MD, Moshe Talpaz, Lisa Kujawski, MD, Yang Liu, Kerby Shedden, Sajid Shakhan, Cheng Li, Ph.D, Harry Paul Erba, MD, PhD, Brian Parkin

Blood (2009) 114 (22): 165.

https://doi.org/10.1182/blood.V114.22.165.165

Published: 2009

Journal Articles

A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia.

Sami Malek, MD, Brian Parkin, Peter Ouillette, Lisa Kujawski, MD, Harry Paul Erba, MD, PhD, Erica L. Campagnaro, MD, Mark S. Kaminski, MD, Kerby Shedden, Kamlai Saiya-Cork

Blood (2009) 114 (22): 2324.

https://doi.org/10.1182/blood.V114.22.2324.2324

Published: 2009

Journal Articles

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

Harry Paul Erba, MD, PhD, Hagop Kantarjian, David F. Claxton, MD, M. Arellano, Roger M Lyons, MD, Tibor J. Kovacsovics, MD, Janice Gabrilove, MD, Stephen Eckert, Ph.D, Rekha Abichandani, MD, Stefan Faderl, MD

Blood (2008) 112 (11): 558.

https://doi.org/10.1182/blood.V112.11.558.558

Published: 2008

Journal Articles

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Shin Mineishi, MD, John Magenau, MD, Attaphol Pawarode, MD, Timothy Buck, Dawn Jones, RN, Koji Kato, MD, David Frame, Pharm.D, Lisa Kujawski, MD, Harry Paul Erba, MD, PhD, Yasser Khaled, MD, Edward M. Peres, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Carrie Kitko, MD, Sung Choi, MD, Gregory A. Yanik, MD, Thomas Braun, PhD, James L.M. Ferrara, MD, John E. Levine, MD

Blood (2008) 112 (11): 2150.

https://doi.org/10.1182/blood.V112.11.2150.2150

Published: 2008

Journal Articles

Changes in the Pattern of Cytogenetic Aberrations with Advancing Age in Acute Myeloid (Non-APL) Leukemia: A Southwest Oncology Study (S9007).

Thomas H. Norwood, MD, Holly M. Gundacker, MS, Marilyn L. Slovak, PhD, Harry Paul Erba, MD, PhD, Frederick R. Appelbaum, MD

Blood (2006) 108 (11): 808.

https://doi.org/10.1182/blood.V108.11.808.808

Published: 2006

Journal Articles

A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS.

Mikkael A. Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD, Harry Paul Erba, MD, PhD, Ronald Sobecks, MD, Anjali Advani, MD, Julie Nichols, RN, Josephine Chan, PhD, Matt Kalaycio, MD

Blood (2006) 108 (11): 2669.

https://doi.org/10.1182/blood.V108.11.2669.2669

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing – Retrospective Review Of The SWOG Experience

Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients

Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I Study

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia.

A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia.

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Changes in the Pattern of Cytogenetic Aberrations with Advancing Age in Acute Myeloid (Non-APL) Leukemia: A Southwest Oncology Study (S9007).

A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only